CareMax — FY2022 Earnings Presentation
14 slides from CareMax's earnings presentation, Mar 9, 2023
Slide 1: Fourth Quarter and Full Year 2022 Earnings Presentation
Fourth Quarter and Full Year 2022 Earnings Presentation March 9, 2023
Slide 2: Disclaimer
Disclaimer Presentation This presentation (“Presentation”) is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other financial instruments, of CareMax, Inc. (“CareMax” or the “Company”) or
Slide 3: CareMax is Driven by a Mission to Deliver Best-in-Class Care
CareMax is Driven by a Mission to Deliver Best-in-Class Care 62 CareMax Medical Centers1 203K Medicare Value-Based Care Members1 ~2,000 Employed & Affiliated Primary Care Physicians1 5-Stars CMS Quality Rating2 245K Total Value-Based Care Members1 10 States1 As of December 31, 2022. Centers for Medi
Slide 4: Fourth Quarter 2022 Update
Fourth Quarter 2022 Update Revenue of $164.3 million, up 39% year-over-year Net income of $10.4 million, compared to net loss of $3.6 million for 4Q211 Adjusted EBITDA (including the impact of de novo pre-opening costs and post-opening losses) of $5.1 million, compared to $3.0 million in 4Q212 69.5%
Slide 5: We Have Built a National Platform for Value-Based Care in the Past Two Years
We Have Built a National Platform for Value-Based Care in the Past Two Years Note: Data as of the applicable year end. Centers Medicare Advantage Members >10x >30x
Slide 6: Full Year 2022 Adjusted EBITDA Performance
Full Year 2022 Adjusted EBITDA Performance Includes one-time expenses to enter new markets and professional fees related to de novo buildouts. Reflects operating losses incurred up to 18 months after center opening. $mm FY22 Recast Guidance FY22 Recast Actual $mm 1 2
Slide 7: Financial Outlook for Full Year 2023
Financial Outlook for Full Year 2023 FY 2022 FY 2023 Guidance YoY % growth Medicare Advantage Membership 93,500 110,000 to 120,000 18% to 28% Revenue $631 million $700 million to $750 million 11% to 19% Adjusted EBITDA1 $22 million $25 million to $35 million 13% to 59% De novo pre-opening costs and
Slide 8: Fourth Quarter 2022 Financial Supplement
Fourth Quarter 2022 Financial Supplement
Slide 9: Reconciliation to Non-GAAP Financial Metrics
Reconciliation to Non-GAAP Financial Metrics 4Q22 Non-GAAP Reconciliation 4Q21 Non-GAAP Reconciliation
Slide 10: Reconciliation to Adjusted EBITDA and Pro Forma Adjusted EBITDA
Reconciliation to Adjusted EBITDA and Pro Forma Adjusted EBITDA1 Net Income to Adjusted EBITDA Bridge 3 2 4 The Company has revised its presentation of Adjusted EBITDA to no longer add back de novo pre-opening costs and post-opening losses and has recast its prior presentation of Adjusted EBITDA. Re
Slide 11: Historical Non-GAAP Financial Summary
Historical Non-GAAP Financial Summary Non-GAAP Income Statement Note: Figures give effect to the Business Combination of CareMax, IMC Health, and Care Holdings as if it had occurred on January 1, 2020. Adjusted EBITDA and Pro Forma Adjusted EBITDA are calculated and presented after de novo pre-openi
Slide 12: Capitalization and Liquidity
Capitalization and Liquidity Diluted Share Count Net Debt (Cash) Excludes unvested warrants as of December 31, 2022. Warrants have a strike price of $11.50/share and (other than the Related warrants) are subject to a $18.00 redemption cap. Warrants are currently out of the money based on CareMax’s c
Slide 13: Total Pro Forma Liquidity
Total Pro Forma Liquidity Reflects undrawn delayed draw facility capacity and maximum allowable revolving commitments after giving effect to the Second Amendment to that certain Credit Agreement dated May 10, 2022. As of the time of this filing, there were no revolving commitments. $mm Ability to ra
Slide 14: Q&A
Caremax Q&A